Niagen Bioscience Reports Strong Q1 2025 Growth

ChromaDex Corporation ( (NAGE) ) has released its Q1 earnings. Here is a breakdown of the information ChromaDex Corporation presented to its investors.

Niagen Bioscience, Inc. is a global bioscience company focused on healthy aging, known for its pioneering research on nicotinamide adenine dinucleotide (NAD+), a key regulator of cellular metabolism. The company commercializes NAD+ precursor nicotinamide riboside chloride (NR) under its flagship ingredient Niagen®.

In its first quarter of 2025, Niagen Bioscience reported a significant financial upswing with total net sales reaching $30.5 million, marking a 38% increase from the previous year. The company also announced a corporate rebranding and a strategic expansion of its NAD+ precursor patent portfolio.

Key financial highlights include a robust gross margin of 63.4% and a net income of $5.1 million, a substantial improvement from the previous year’s net loss. The company’s adjusted EBITDA also saw a notable increase to $4.9 million. Additionally, Niagen Bioscience ended the quarter with a strong cash position of $55.6 million.

Looking ahead, Niagen Bioscience anticipates continued growth, projecting a 20% to 25% increase in net sales for the full year 2025. The company plans to enhance its e-commerce presence, expand partnerships, and increase pharmaceutical-grade Niagen® sales, while maintaining a focus on research and development to drive future innovation.